Loading patent…
AssigneeVirginia Tech Intellectual Properties, Inc.
InventorsXiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
Estimating the term…
The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products.
An infectious chimeric nucleic acid molecule of porcine circovirus (PCV1-2) comprising a nucleic acid molecule encoding an infectious, nonpathogenic PCV1 which contains an immunogenic open reading frame (ORF) gene of a pathogenic PCV2 in place of an ORF gene of the PCV1 nucleic acid molecule.
An immunogenic polypeptide having the amino acid sequence set forth in SEQ ID NO:4 or a biologically active variant thereof.
A viral vaccine that protects a pig against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2 comprising a nontoxic, physiologically acceptable carrier and an immunogenic amount of a member selected from the group consisting of:
An infectious PCV2 molecular DNA clone having ATCC Patent Deposit Designation PTA-3913 or a PCV2 DNA clone derived therefrom.
An infectious reciprocal chimeric nucleic acid molecule of PCV2-1 comprising a nucleic acid molecule encoding an infectious, pathogenic PCV2 which has an immunogenic ORF2 gene from a nonpathogenic PCV1 in place of an ORF2 gene of the PCV2 nucleic acid molecule.
Dependencies are inferred from the claim text.